Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2021-07-05. The firm offers customized assay development and manufacturing services for POC tests and digital reader platforms. The company also directly develops, manufactures, and commercializes Lumos-branded POC tests that target infectious and inflammatory diseases. Its Products offering is based on developing and commercializing its own suite of POC diagnostic products which are primarily focused on the diagnosis and management of infectious diseases. These include FebriDx, a POC test for detecting and differentiating viral and bacterial respiratory infections, and ViraDx, a rapid point-of-care diagnostic product that simultaneously tests for acute respiratory infections caused by the COVID-19, influenza A, and influenza B viruses. The company manages the full development program for POC assays.
